BioSpace recently revealed its NextGen Bio Class of 2023, which features top life science startups in North America. The top companies were evaluated based on finance, partnerships, pipeline, growth potential and innovation.
Among the list of growing companies is Seattle-area startup, Affini-T Therapeutics. The company is recognized for its unique work with a T Cell Receptor (TCR) discovery engine and a suite of synthetic biology components. The company’s most recent $175 million funding round and new partnership with ElevateBio are key contributors in the company’s growth potential and innovation.